Introduction
Chondrocyte-mediated degradation of articular cartilage has been suggested as a major factor in the pathogenesis of various Therapeutic strategies aimed at developing biological chondroprotective agents are faced with the challenge of targeting these proteins to the immediate microenvironment of articular chondrocytes. These problems are exacerbated by the fact that cartilage is an avascular and largely nonreplicative tissue. Given the limitations of traditional methods of biological drug delivery, gene therapy offers a new approach for the possible treatment of human arthritis. Both ex vivo and in vivo techniques using viral and nonviral vectors have been used to deliver the Escherichia coli /i-galactosidase (lacZ), neomycin resistance genes, and the IL-I receptor antagonist (IL-Ira) cDNA to synoviocytes (7) (8) (9) (10) (11) (12) . However, these same gene delivery techniques used to target synoviocytes have been unsuccessful in delivering genes to articular chondrocytes. Although delivery of expression vectors encoding soluble proteins to synoviocytes has been shown to be effective in inhibiting proinflammatory cytokine effects, the direct effect of these maneuvers on chondrocytemediated cartilage degradation remains to be determined (10, 11) . These results once again emphasize the need for the development of models for direct gene transfer to articular chondrocytes.
Recently, it has been demonstrated that human chondrocytes can be expanded in tissue culture and used for autologous transplantation onto articular cartilage. When these cells are applied to full thickness cartilage defects and sealed over with a periosteal flap, this treatment can lead over time to the growth of tissue within the defect that resembles normal articular cartilage (13) . This treatment has only been applied to more or less solitary lesions in an otherwise normal joint, and it has yet to be seen whether chondrocyte transplantation alone would be sufficient to heal the defects associated with OA cartilage. Nevertheless, the success of autologous chondrocyte transplantation suggests it may be used in combination with ex vivo gene transfer to enhance the therapeutic potential of these cells.
The degradation of cartilage extracellular matrix (ECM) observed in OA is a complex process that at some level can be defined as the end result of catabolic processes outstripping anabolic processes (5, 6) . IL-1, a cytokine present in OA joint fluid (14, 15) has direct (chondrocyte-mediated) and indirect (synoviocyte-mediated) catabolic effects on articular cartilage (15, 16) . These effects include generation and maintenance of synovial inflammation (17) , as well as up-regulation of matrix metalloproteinase (18) and PG expression (19) .
We hypothesized that IL-I-mediated catabolic effects on articular chondrocytes are amenable to inhibition via transgenic overexpression of IL-I antagonists by chondrocytes. Further, we chose to examine the interleukin-I receptor antagonist protein as a prototypic IL-I inhibitor. IL-Ira is a naturally occurring protein that is considered to be a potentially therapeutic biological agent (20, 21) . IL-Ira is a soluble protein that can bind to types I and type II IL-i receptors but is unable to mediate signal transduction through these receptors (22). There have been a number of in vitro and in vivo studies demonstrating the antiinflammatory effects of IL-lra, and an extensive review of this literature has been published (23) .
We have previously reported the construction and functional characterization of a recombinant human adenovirus that can mediate the high level expression of IL-ira (10) . In (24) . Transgene transcription was driven by the early enhancer/promoter of the cytomegalovirus (CMV) in the vector Ad.-CMV lacZ and the Rous sarcoma virus (RSV) long-terminal repeat in the vectors Ad.RSV ntlacZ and Ad.RSV hIL-ira. An SV40 polyadenylation sequence was cloned downstream from each of these reporters (9, 10) . The vector Ad.RSV n tlacZ contains a nuclear targeting (designated as nt) epitope linked to the 5 ' end of the lacZ gene, and as a result, the cells transduced with this gene can be identified by the presence of blue nuclei after reaction with the chromogenic substrate 5-bromo-4-chloro-3-indolyl-3-D-galactoside (X-gal).
Transduction of chondrocytes. Primary human chondrocyte cultures were trypsinized and seeded in six-well tissue culture plates at a density of 0.5-1.0 x 106 cells/well. After the cells were 70% confluent, they were washed two times with serum-free DME, infected with Ad.-CMVlacZ, Ad.RSVntlacZ, or Ad.RSVIL-Jra (viral titers = 1010 plaque-forming units/ml; diluted 1:100 in serum free DME) at an approximate moi of 103 plaque-forming units/cell, for 2 h at 37TC. Cells were then washed two times in fresh DME, containing 10% FCS, 100 U/ml penicillin G sodium, 100 Mg/ml streptomycin sulfate, and 0.25 Mg/ml amphotericin B, and the cells were allowed to grow for 24 h at 37TC. Mock-infected cells were maintained in parallel. 24 h after plating, cells were fixed, reacted with X-gal solution, rinsed, and photographed.
Chondrocyte transplantation. Transduced allogeneic chondrocytes were trypsinized, suspended in 1-3 ml of complete Ham's F-12 medium, and added slowly onto the articular surface of cartilage organ cultures or intact cartilage (with the underlying subchondral bone) selected for transplantation experiments. To achieve optimal conditions for adherence of cells to the articular surface, cartilage pieces were pretreated with 10-20% serum, 0.5% gelatin, or 3.5 jug Cel-Tak® (Collaborative Biomedical Products, Bedford, MA)/cm2 surface area. In most of the experiments, complete F-12 (containing 10% serum) used for maintaining the cartilage organ cultures was sufficient for adherence of cells to cartilage. 24 h after infection with adenoviral vectors, chondrocytes were trypsinized and added to cartilage organ cultures. Approximately 0.5-1.0 x I0 cells were added to each cartilage piece, and the cultures incubated for 48 h in complete F-12 medium at 37°C. In some of the experiments, to prevent cells from settling onto the plastic, the bottom surface of the tissue culture plates were siliconized and cartilage slices placed into these wells before the addition of chondrocytes.
In situ staining for ,B-galactosidase transgene expression. Chondrocytes and cartilage organ cultures were washed in PBS and fixed in 2% paraformaldehyde in 100 mM Pipes, pH 6.9, for 30 min. Samples were washed for 30 min in PBS/2 mM MgCl2 and reacted in 5 mM K3Fe (CN)6, 5 mM K4Fe (CN)6, 2 mM MgCl2 0.01% sodium deoxycholate, 0.02% NP-40, and 1 mg/ml X-gal in PBS for 4 h at 37°C (25). Chondrocytes were then washed three times with PBS, postfixed for 2 h in 2% paraformaldehyde/1% glutaraldehyde, counterstained with neutral red, and photographed using light microscopy. At Scanning electron microscopy. Cartilage slices used for transplantation experiments were examined by scanning electron microscopy to identify integration of transduced cells into the articular surface. Cartilage disks analyzed by scanning electron microscopy were trimmed by sharp dissection to a width of 1 mm and fixed in 4% paraformaldehyde Transplantation of Ex Vivo-transduced Chondrocytes Is Chondroprotective in PBS followed by 1% glutaraldehyde in 0.5 M cacodylate buffer. Disks were dehydrated in graded alcohols, desiccated under vacuum, and coated with elemental gold, then imaged using a scanning electron microscope (ISI DS-130, Topcon, Milpitas, CA).
Effects of exogenous IL-1 administration on transgene expression and ECM degradation in vitro. 24 h after infection, the chondrocytes were trypsinized, washed, and plated onto human OA cartilage organ cultures, and the cultures were incubated in complete F-12 medium at 370C. 48 h after transplantation of chondrocytes, cartilage organ cultures were rinsed with 1 ml F-12 nutrient mixture (GIBCO BRL) (without serum) to remove residual FCS. Each treatment group was done in triplicate. The controls received 1 ml F-12 medium + 10 ul PBS with 0.1% BSA and IL-I treatment group received 1 ml F-12 medium + 10 ld IL-la (500 U). Cartilage organ cultures were incubated for 10 d.
Every 48 or 72 h conditioned medium was replaced with fresh medium and IL-i or PBS/BSA was added. All media changes were collected. At the end of the experiment, the cartilage pieces were subjected to papain digestion: cartilage pieces were digested in 24-well plates by adding 50 tl papain in 1.0 ml cysteine buffer (0.1 M phosphate buffer, pH 7.0, containing 0.1 M L-cysteine HCl and 0.05 M EDTA) and incubated at 560C until the cartilage pieces were dissolved completely.
The effect of IL-i on proteoglycan degradation was determined by analyzing the cartilage digests and media samples collected for chondroitin sulfate content, using the modified 1,9-dimethylmethylene blue assay (26) . The conditioned media were also analyzed by ELISA (R& D Systems Inc., Minneapolis, MN) and the total amount of human ILIra (endogenous and transgenic) was calculated. Statistical analysis of the data was performed using one way ANOVA followed by StudentNewman-Keul's method of pairwise multiple comparisons.
Results
Transduction of human chondrocytes. To (Fig. 1 A) (Fig. 1 B) . However, as expected for chondrocytes maintained in monolayer culture, a percentage of cells (-40%) also coexpressed type I collagen (Fig. 1 C) . These Transplantation of transduced chondrocytes. Transplantation of chondrocytes transduced with the lacZ and IL-ira genes were undertaken as a means to overexpress transgenic proteins (Fig.  2 A) . Cartilage samples seeded with mock-transfected cells showed no evidence of cells with blue staining nuclei (Fig. 2  B) , indicating that lacZ expression on the articular surface was specific for the Ad.RSV ntlacZ-transduced chondrocytes. Examination of cartilage organ cultures containing intact subchondral bone also revealed multiple foci of blue staining chondrocytes (transduced with Ad.CMV lacZ) present on the articular surface (Fig. 2 C) . Control samples seeded with mocktransfected cells were negative for blue-staining cells (Fig. 2  D) . These results support the concept that transduced chondrocytes can adhere to the surface of human OA cartilage, remain viable, and continue to express transgenic protein.
Scanning electron microscopy. Cartilage organ cultures seeded with lacZ-transduced chondrocytes (Fig. 3 A) were then examined by scanning electron microscopy. Examination of the OA cartilage organ cultures revealed that foci of transduced chondrocytes were present across the articular surface of seeded disks ( Fig. 3 B and C) but were not found on unseeded control disks (Fig. 3 D) . Fig. 3 B shows transplanted chondrocytes present on the surface of OA articular cartilage organ cultures that are embedded within a territorial extracellular matrix. At a higher magnification (Fig. 3 C) adherent cells display an irregular surface as well as interconnecting cytoplasmic processes, characteristics of viable chondrocytes from OA human articular cartilage (27) . A considerable amount of matrix material resembling collagen fibers also surrounds each cell. These results confirm the results obtained by stereoscopic microscopy and suggest that transduced chondrocytes can both adhere to and integrate into the surface of OA cartilage presumably through the elaboration of new ECM proteins.
Transduction ofchondrocytes with the human IL-i ra cDNA. The purpose of these experiments was to determine if chondrocytes transduced with the human IL1-ra cDNA and transplanted onto the surface of cartilage organ cultures can appropriately process and secrete a biologically active human cytokine antag- Fig. 1 B) showed the surface of the tissue to be acellular. x32.
onist. Cartilage organ cultures containing chondrocytes transduced with Ad.RSVIL-Jra expressed and secreted on an average 1 Hg/mI of human IL-Ira over a 10-d period; whereas cartilage cultures containing chondrocytes transduced with Ad.-RSV ntlacZ produced on an average 100 pg/ml of IL-Ira (Fig.  4 , ANOVA: P < 0.0001, F = 56.7, n = 16). Identical groups of organ cultures continuously exposed to recombinant human IL-la (500 U/ml) showed no statistically significant increase in the expression of human IL-ira (Student-Newman-Keuls method of pairwise multiple comparison: P < 0.05). Thus, transduced chondrocytes growing on the articular surface of OA cartilage can appropriately express, process, and secrete an immunoreactive transgenic protein. Furthermore, the expression of the transgenic IL-Ira is independent of endogenous regulation and can be sustained at high levels for at least 10 in vitro.
Chondrocytes transduced with the human IL-ira cDNA inhibit IL-I effects in OA cartilage cultures. To examine whether transplantation of chondrocytes transduced with the IL-ira cDNA is chondroprotective, cartilage cultures were incubated in the presence or absence of exogenous IL-la (500 U/ml) for 10 d and total proteoglycan degradation of tissue was determined. As shown in Fig. 5 , OA organ cultures seeded with ILlra-transduced chondrocytes and treated with exogenous IL-1 lost a mean of 11.7% of total proteoglycan content over the 10-d period of observation. Identical OA organ cultures seeded with lacZ-transduced chondrocytes lost a mean of 23.3% total proteoglycan content over the same time period. Control cultures containing lacZ-or IL-ira-transduced chondrocytes that were unstimulated with IL-I had a mean total proteoglycan loss of 11.2%. These data indicate that chondrocytes transduced with the IL-Ira cDNA when present as integrated cells on the surface of OA articular cartilage were able to inhibit IL-i-mediated chondrocyte degradation of ECM at a statistically significant level (ANOVA: P < 0.0001, F = 12.5, n = 34; Student-Newman-Keuls method of pairwise multiple comparisons: P < 0.05). The results obtained from the unstimulated control cultures indicate that the increased loss of ECM from the IL-1-stimulated cultures was specific for the exogenous cytokine.
These experiments indicate that transduced chondrocytes are able to express, process, and secrete a biologically active 
Discussion
Strategies aimed at the development of chondroprotective biological agents for the treatment of human GA face the challenge of delivering these agents directly to the surface of abnormal articular cartilage. Previous work has indicated that chondrocytes participate directly in the pathophysiological events that trigger ECM destruction in hyaline cartilage (1) (2) (3) (4) (5) (6) . Current methods (systemic or intraarticular administration) for the introduction of biological agents into the joint space may fail to provide sustained proximal effects to the ECM within the microenvironment surrounding articular chondrocytes, presumably the area of greatest risk for the destructive effects mediated directly by the GA chondrocytes. This report describes a method of ex vivo gene transfer to articular chondrocytes that may allow circumvention of many of the problems inherent in the delivery of recombinant proteins to articular cartilage. In this report we have modeled in vitro a method for the transduction and transplantation of genetically modified chondrocytes onto the surface of GA articular cartilage using a continuous cartilage organ culture system. As determined by in situ staining for lacZ protein, the transduced chondrocytes adhered to GA cartilage, remained viable, and expressed transgenic protein for at least 8 d of continuous culture (Fig. 2 A) . Examination of the seeded cartilage tissues by scanning electron micros- copy provided additional evidence that the transplanted cells maintained viability and were able to begin the process of integration into the existing surface matrix through the elaboration of new ECM.
We chose to examine the effects of adenoviral-mediated overexpression of the human IL-lra as a prototypic chondroprotective protein. The recombinant IL-lra protein is under study as a potentially therapeutic biological agent able to counteract in vivo the proinflammatory effects of IL-1, a cytokine recognized to function as a central mediator of inflammation and cartilage degradation (14) (15) (16) (17) (18) (19) . Human chondrocytes transduced with an adenovirus containing the cDNA for IL-lra (Ad.-RSV hIL-ira) were able to elaborate large amounts of this potentially chondroprotective transgenic protein and continued to secrete this protein after adherence to the cartilage surface when maintained as a continuous cartilage organ culture. The results of these studies indicate that transduced chondrocytes express quantities of biologically active IL-Ira that is sufficient to counteract the IL-I induced proteoglycan degradation from OA cartilage organ cultures over a period of at least 10 d of continuous exposure to the proinflammatory signal. This is a noteworthy achievement in that it has not been possible to demonstrate chondroprotection by delivery of recombinant IL-Ira using traditional routes of delivery (28, 29) .
Transplantation of heterologous or autologous chondrocytes has already been evaluated as a treatment for the repair of focal articular defects in several animal models (30) (31) (32) . Recently, autologous chondrocyte transplantation has been successfully applied to the treatment of isolated cartilage defects in a series of human patients ( 13) . Because cartilage degradation in OA is the end result of a complex interaction of catabolic and anabolic processes, it remains to be seen whether the transplantation of autologous chondrocytes alone would be sufficient to allow appropriate repair of OA cartilage. It is reasonable to hypothesize that it will be necessary to initially inhibit the degradative process before appropriate repair can occur as a consequence of cellular transplantation. In this study we chose to combine chondrocyte transplantation with ex vivo gene transfer as a means to augment the biological effects of these cells, specifically in terms of the ability of transplanted cells to provide a sustained source of chondroprotective proteins.
In general, ex vivo gene transfer strategies have used recombinant retroviruses as gene transfer vectors (8) (9) (10) (11) . Our results using recombinant adenoviruses as ex vivo gene transfer vectors for chondrocytes suggest several potential advantages over the use of recombinant retroviruses. Primary among these is the high efficiency of transduction (> 90% at an moi of 103) that can be achieved without the need for prolonged monolayer culture or the use of selectable marker genes. Short term monolayer culture allows the chondrocytes to retain many of the markers associated with the differentiated chondrocyte phenotype and in turn this may facilitate adherence and integration of the transduced cells onto the articular surface at the time of transplantation. Other advantages include virtually no risk of insertional mutagenesis and the possibility of coinfection using multiple vectors to mediate the simultaneous expression of two or more transgenic proteins. Our findings indicate that ex vivo transduction followed by autologous transplantation of human chondrocytes is a viable strategy for intraarticular gene therapy. Further development of this system using in vivo animal models may allow the development of novel molecular approaches for the treatment of OA and a variety of other human arthropathies.
